Our lead products in development are T-cell engagers that target multiple tumor types. Our T-cell engagers have high affinity tumor target binding, long half-life, low immunogenicity, and induce minimal cytokine release with targeted T-cell (Teff) activation and killing and minimal regulatory T-cell (Treg) stimulation—ultimately leading to sustained tumor lysis in a safe, tolerable way. This has been demonstrated by in vitro, in vivo and ex vivo studies for multiple tumor types, including multiple myeloma, prostate, lymphoma and ovarian.
TNB-383B, an anti-CD3/BCMA bispecific, is currently in Phase 1 of development for the treatment of multiple myeloma. For more information on TNB-383B and our additional clinical studies, please visit our Clinical Trials page.